Adamas Presents Nonclinical Findings Supporting the Potential Use of ADS-5102 for the Treatment of Multiple Sclerosis Gait

Adamas Pharmaceuticals, Inc.

today announced findings from two nonclinical studies that demonstrate the potential of ADS-5102 for the treatment of multiple sclerosis (MS) symptoms. One study demonstrated improvement in walking in in vivo models of MS. Data from the second study provide insights into the potential mechanisms of action of amantadine in MS. These results (Abstract P863) were presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) held in Barcelona, Spain. "We are encouraged by these nonclinical data and what they mean with respect to the potential of ADS-5102, our extended release version of amantadine, in addressing MS-related symptoms, including walking impairment," stated Natalie McClure, Ph.D., Senior Vice President of Product Development at Adamas Pharmaceuticals, Inc. "With the improved pharmacokinetic profile of ADS-5102, we can potentially administer higher therapeutic doses than is common with immediate release amantadine." Researchers conducted nonclinical studies designed to evaluate the efficacy of amantadine for the treatment of MS-related symptoms, including walking impairment, in in vivo models of MS and to better understand the mechanisms of action of amantadine in MS. Data demonstrated that in models of MS, chronic administration of amantadine at a dose intended to match the human plasma levels of ADS-5102 improved walking. Additionally, data from an in vitro study demonstrated that amantadine blocked neuronal potassium channel activity, which may result in enhanced electrical impulses across demyelinated regions of neurons. Data from these studies suggest that ADS-5102 may have clinical utility in the treatment of major symptoms associated with MS, including walking impairment. In June 2015, Adamas announced the initiation of a Phase 2 clinical trial of ADS-5102 for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The study, which will enroll approximately 60 patients, is designed to evaluate the safety and tolerability of ADS-5102 dosed at 340 mg once daily at bedtime in an MS population. Efficacy measurements include assessments of walking and fatigue. The treatment duration is four weeks with top-line results anticipated in 2016.